Astellas Unit, Pfizer Sue To Bar Roxane's Generic Tarceva

Law360, New York (April 13, 2012, 2:17 PM EDT) -- Astellas Pharma Inc. unit OSI Pharmaceuticals LLC, Pfizer Inc. and Genentech Inc. on Friday sued Roxane Laboratories Inc. in Delaware federal court over Roxane’s bid for approval to market a generic version of the cancer treatment Tarceva.

The lawsuit asserts three patents and names Boehringer Ingelheim Corp. subsidiary Roxane as the sole defendant. Genentech is a co-exclusive licensee of all three patents. OSI, which Astellas bought for $4 billion in 2010, owns two of the patents and co-owns the third with Pfizer, according to the complaint....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.